Background Biotin is a water-soluble vitamin which plays an important biochemical role in a variety of carboxylase-mediated metabolic reactions. Determination of biotin status for the diagnosis of biotin deficiency is crucial.
Introduction
Measurement of plasma biotin concentration is generally regarded as a reliable indicator of biotin status. Biotin is a water-soluble vitamin which participates in a variety of carboxylase-mediated metabolic reactions. Clinical studies have described inborn errors of biotin metabolism resulting in biotin-dependent carboxylase de¢ciency 1 or unpaired biotin absorption and transport. 2 Biotin de¢ciency has also been reported following parenteral nutrition. 3 Several methods have been described in the literature for the determination of biotin concentration. 4 Early methods were microbiological in principle and were long and cumbersome. 5 More advanced techniques involved avidin or streptavidin in protein-binding assays. 6^11 Radioligand assays use labelled biotin or avidin. Due to the low speci¢c-activity of the tracers, assays involving 14 C-or 3 H-labelled biotin lacked su¤cient sensitivity to measure physiological concentrations. Because biotin is sensitive to oxidation, it cannot be directly radioiodinated. New [ 125 I]iodobiotin derivatives of high speci¢c activity were further synthesized. Because these derivatives are biotinamides and therefore sensitive to biotinidase activity, biological samples need prior treatment with a biotinidase inhibitor. 8, 11 [ 125 I]iodoavidin derivative, labelled in a two-step method, was used by Mock and Dubois 7 in a sequential solid-phase assay of biotin. Non-radioactive avidin was used in competitive enzyme -linked immunosorbent assays. 12^15 Here, we describe a robust competitive solid-phase assay using iodostreptavidin as a speci¢c binding reagent which is directly iodinated and insensitive to biotinidase. The absence of non-speci¢c protein binding allows the direct measurement of plasma samples.
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Materials and methods
Reagents
All reagents were of analytical grade. Biotin and biotinylated goat antirabbit IgG were obtained from Sigma Chemical Co. (St Louis, MO, USA). Streptavidin was obtained from Calbiochem (La Jolla, CA, USA). Bovine serum albumin (BSA, fraction V) was purchased from IBF (Villeneuve la Garenne, France).
Na 125 I (code IMS 30) was purchased from Amersham International (Amersham, UK). Nunc Immuno tubes, maxi sorp quality, were from Nalge Nunc International (Roskilde, Denmark). Sephadex G50 was obtained from Pharmacia (Uppsala, Sweden).
Phosphate -bu¡ered saline (PBS) pH 7 ¢ 4 consisted of NaCl 138 mmol/ L, Na 2 HPO 4 8¢3 mmol/ L, KH 2 PO 4 1¢7 mmol/L, KCl 2¢7 mmol/ L. All the other reagents were obtained from Merck (Darmstadt, Germany).
Synthesis of [ 125 I]iodostreptavidin
Streptavidin was iodinated according to the method of Hunter and Greenwood. 16 Streptavidin, 20 mg in 40 mL of 250 mmol/ L PBS pH 7¢4, was added to a reaction vial containing 500 mCi (18¢5 MBq) of carrier-free 125 I (100 mCi/mL or 3 ¢ 8 GBq/mL). Chloramine T (10 mL of 2-mg/mL solution) was added to the mixture and allowed to react for 30 s. The reaction was then stopped by the addition of 50 mL of sodium metabisulphite (15 mmol/ L). The reaction mixture was diluted with 1mL of PBS containing 5 g/L BSA. [ 125 I]iodostreptavidin was separated from free iodine by passage on a Sephadex G50 column (1620 cm). Fractions corresponding to the ¢rst peak containing [ 125 I]iodostreptavidin were pooled and stored at 7208C. The iodination yield was calculated from the elution pattern. The speci¢c activity, given in mCi/mg, was calculated from the absolute activity of 125 I, the mass of streptavidin utilized in the labelling and the iodination yield. Standard curves with di¡erent dilutions of radioligand were tested to determine the optimal condition for the assay.
Biotin-immobilized tubes
Tubes were coated with biotinylated goat antirabbit IgG. Biotinylated goat antirabbit IgG was previously diluted in PBS and 200-mL aliquots were pipetted into the Nunc Immuno tubes. After a 2-h mixing incubation at room temperature (or at 48C for 16^20 h), the unbound IgG was removed by aspiration and the tubes were washed twice with 500 mL of PBS solution. To block the remaining available sites, 500 mL of PBS solution containing 1% BSA were added to each tube. After mixing for 1h at room temperature, the solution was removed by aspiration and the tubes were washed twice with 500 mL of PBS solution before use. In order to evaluate the non-speci¢c binding, Nunc Immuno tubes were similarly treated, but omitting the biotinylated IgG. The dilution of biotinylated IgG for coating and the optimal dilutions of iodostrepavidin were tested.
Preparation of biotin standard curve
Biotin was ¢rst removed from pooled plasma by mixing 100 mL of pooled plasma with 4 mg of Gardenal (Specia, Rhoª ne Poulenc Rorer, Montrouge, France) for 4 h at room temperature. The plasma was then dialysed against 4 L of PBS using Spectra-Por cellulose (Spectrum, Houston,TX, USA).
A biotin solution (49 nmol/ L) was prepared in PBS containing 1 g/L BSA. This solution was stored at 7208C. Diluted preparations of this solution were then added to the dialysed biotin-free plasma to give a standard curve with the following biotin concentrations: 0, 0¢20, 0¢41, 0¢82, 1¢23, 1¢64 and 2¢46 nmol/ L.
Assay protocol
Standards, controls and plasma samples (100 mL) were pipetted in duplicate into biotin-coated tubes. Then 100 mL of [ 125 I]iodostreptavidin diluted in PBS containing 1g/L BSA were added to each tube. After a 2-h incubation at room temperature, the unbound streptavidin was removed by aspiration, then the tubes were washed twice with PBS and counted in a gammacounter (Multigamma, LKB, Bromma, Sweden). B 0 , the fraction of iodostreptavidin bound to the biotincoated tubes in the absence of biotin standard, and B, the fraction bound at known biotin concentration, were determined. A standard curve of B/B 0 versus biotin concentration was prepared and the best ¢t drawn. The biotin concentrations in tests and controls were determined from this curve.
Analytical performance
The dilution of linearity was tested by diluting plasma samples displaying high and normal biotin concentrations. To ascertain analytical recovery, known amounts of biotin were added to a stock plasma pool and then assayed. Ten replicated standard curves were run with two controls in ten series (one assay per week) to determine the inter-assay precision. Ten replicate controls were assayed on the same day to determine the intra-assay precision. The detection limit was represented by the zero-dose intercept of the precision pro¢le. 17
Reference values
In all cases, blood was collected into EDTA, and plasma was separated by centrifugation and stored at 7208C until assayed. We determined the concentration of biotin in the plasma of 47 normal healthy adults (age 23^59 years, 34 women, 13 men), 12 pregnant women and 24 patients su¡ering from renal failure, taken at random times during the day. In addition, plasma biotin concentration was measured in a healthy volunteer after oral administration of 5 mg of biotin.
Results
The retained dilution of biotinylated IgG for coating was 1/2400. Tubes were coated at an approximate IgG concentration of 200 ng/mL, as recommended by the producer. They were stable for up to 10 days if stored at 48C and ¢lled with PBS solution. Streptavidin was iodinated reproducibly with a yield of 60^65%. The speci¢c activity was estimated to be 15 mCi/mg. Sensitivity of the assay was in£uenced by the [ 125 I]iodostreptavidin dilution. 15 As shown in Fig. 1 , a tracer amount of 0¢4 ng/tube is more e¡ective for determination of low biotin concentrations, whereas a tracer amount of 3 ¢ 5 ng/tube is better for high biotin concentrations. The detection limit could be lowered by up to 0¢82 pmol/L depending on the amount of tracer used. An amount of 1¢9 ng of streptavidin per tube was chosen, however, as a compromise, to give an assay reliable enough to measure plasma biotin concentrations over as wide a range as possible (0¢202 ¢46 nmol/ L) (Fig. 2 ). This gave a detection limit of 0¢11nmol/ L. Therefore the optimal dilution of iodostreptavidin was determined immediately after the labelling and remained unchanged, without taking account of the tracer radioactive decrease. The tracer stored at 7208C could be used for up to 5 months after iodination, as demonstrated by the B/B 0 value and the detection limit both remaining constant during this time (Fig. 2) . The increase in temperature and incubation time favoured the tracer binding. We retained a 2-h mixing incubation time at room temperature, which produced a maximum binding B 0 of 65%.
Validation
The assay was linear, following dilution of plasma samples with biotin-free plasma, up to a biotin concentration of 2 nmol/ L (Fig. 3) . Mean (SD) biotin recoveries from the stock plasma sample spiked with 0¢20 and 0¢41 nmol/ L of biotin were 93% (7%) and 103% (6%). Intra-and inter-assay coe¤cients of variation were 3¢5% and 10%, respectively.
Reference values
The mean [standard deviation (SD)] concentration of biotin in the plasma of 47 healthy adults randomly taken during the day was found to be 0¢73 (0¢26) nmol/ L, range 0¢45^1¢60 nmol/ L. Mean values for plasma biotin concentration obtained from pregnant women (nˆ12) and from patients displaying abnormal renal function (nˆ24) were 0¢54 nmol/ L and 4¢64 nmol/L, respectively (Fig. 4) . Plasma biotin concentration measured in a healthy volunteer 1h after the oral administration of 5 mg of biotin was 500 times the pre-loaded level; this then slowly declined.
Discussion
We describe here a convenient, rapid and robust assay for the determination of biotin in plasma. This assay shows the advantage of a direct one-step assay and requires only a small volume of sample. The use of gamma-emitting iodotracers improved sensitivity and practicability of assays but needed a two-step synthesis. For this purpose, 3-(p-hydroxyphenyl)propionyl avidin was ¢rst synthesized, then radioiodinated. We overcame this di¤culty by direct iodination of streptavidin which led to a 60% labelling yield. The low speci¢c activity allows a long time use without damage of the tracer. Maximum binding in the absence of biotin was typically 60^80%, and non-speci¢c binding did not exceed 0 ¢ 7% of total activity. By modi¢cation of the amount of streptavidin, a wide range of biotin concentrations could be measured. The assay was usually calibrated with approximately 1¢9 ng of streptavidin per tube, which was suitable for measuring biotin in the plasma of normal or de¢cient subjects. The detection limit, which was routinely set at 0¢11 nmol/ L, and the analytical range could, however, be increased by altering the amount of strepavidin.
Gardenal was added to plasma to inhibit the biotinbinding to biotinidase and to facilitate the removal of biotin from plasma by dialysis. The addition of biotinfree plasma to the standard curve, in order to ensure a plasma-based matrix, helped ensure that plasma samples gave linear results when analysed on dilution. The evaluation of biotin status requires a speci¢c and sensitive analytical method. Metabolites must be distinguishable from biotin which is the only biologically active compound. The microbiological method using Lactobacillus plantarum (ATCC 8014), which is highly speci¢c, measures only biotin and biotin sulphoxide. The avidin-binding methods detect a range of metabolites and need previous chromatographic separation to speci¢cally measure biotin. The speci¢city of the streptavidin-binding assay is better in plasma and is comparable to the L. plantarum assay, 18 but equally recognizes biocytin and biotin. Because biocytin does not accumulate in high concentrations in plasma but is excreted in urine, especially in patients with biotinidase de¢ciency, biotin levels are found to be low in this situation with streptavidin-binding assays. 19 In healthy subjects, we observed plasma concentrations in concordance with those obtained with microbiological assays, ranging from 0¢82 to 1¢64 nmol/ L. In contrast, higher plasma levels were reported using other binding assays, 6, 8, 9 ranging from 0¢41 to 3¢44 nmol/ L. Measurement of plasma samples obtained from pregnant women and from patients su¡ering from renal failure gave low and high values, respectively, in agreement with previous ¢ndings. 8 In conclusion, this robust and sensitive assay is suitable for screening for biotin de¢ciency, which itself is not a rare event, especially in patients receiving parenteral nutrition.
